The Molecular Pathology of Myelodysplastic Syndrome.

Abstract excerpt

The diagnosis and classification of myelodysplastic syndromes (MDS) are based on cytomorphology and cytogenetics (WHO classification). Prognosis is best defined by the Revised International Prognostic Scoring System (IPSS-R). In recent years, an increasing number of molecular aberrations have been discovered. They are already included in the classification (e.g., SF3B1) and, more importantly, have emerged as...

Topics

Join the communities discussing this publication.

• Biomarkers
• Isocitrate Dehydrogenase
• Mutation
• Myelodysplastic Syndromes
• Pathology, Molecular